WEAA0106LB - The potential of attenuated Mycobacterium tuberculosis or BCG vaccines to...

Tuberculosis vaccine development by H McShane, Oxford UniversityПодробнее

BCG Centenary SymposiumПодробнее

Session 2 - TB HIV 2019 Willem HanekomПодробнее

VALIDATE Seminar Development of recombinant BCG Vaccine for tuberculosis utilizing Major MembraneПодробнее

Helen McShane: Challanges in TB vaccine developmentПодробнее

Global Health Seminar - TB vaccines in Children: Past, Present and FutureПодробнее

TB vaccine updateПодробнее

HIVR4P // Virtual SA03 HIV & TB: An R&D tale of two vaccines (Part 2/3)Подробнее

VALIDATE Seminar Spore FP1 mucosal vaccine candidate for TBПодробнее

ESPID 2020: The Non-Specific Effects of BCG Vaccination – Trials and Tribulations by Nigel CurtisПодробнее

BCG vaccine contamination with virulent Mycobacterium bovis strain [The Lübeck disaster (1930)]Подробнее

Heterologous Boost Following Mycobacterium Bovis BCG Reduces the Late PersistentПодробнее

BCG vaccineПодробнее

BCG Then and Now: A Public Lecture from the VALIDATE NetworkПодробнее

BCG vaccine of Tuberculosis | Dr. Conrad fischerПодробнее

BCG Vaccine: Your Shield Against TuberculosisПодробнее

Bacillus Calmette–Guérin (BCG) Vaccination & COVID-19Подробнее

TB vaccine updateПодробнее

From biomarkers to vaccines: how immunology can help end TBПодробнее